QNTM Stock Overview A biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Quantum BioPharma Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Quantum BioPharma Historical stock prices Current Share Price CA$4.21 52 Week High CA$96.20 52 Week Low CA$3.90 Beta 0.82 1 Month Change -44.97% 3 Month Change -22.47% 1 Year Change -94.82% 3 Year Change -95.20% 5 Year Change -99.12% Change since IPO -99.73%
Recent News & Updates
New major risk - Share price stability Dec 22 Quantum BioPharma Ltd. announced that it expects to receive CAD 5 million in funding Dec 05
New major risk - Financial position Nov 13
Quantum BioPharma Regains Nasdaq Listing Compliance Sep 09
Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next" Aug 30 Quantum BioPharma Ltd. Announces Executive Appointments See more updates
New major risk - Share price stability Dec 22 Quantum BioPharma Ltd. announced that it expects to receive CAD 5 million in funding Dec 05
New major risk - Financial position Nov 13
Quantum BioPharma Regains Nasdaq Listing Compliance Sep 09
Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next" Aug 30 Quantum BioPharma Ltd. Announces Executive Appointments
New major risk - Financial position Aug 15
FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price Requirement Aug 13
New major risk - Shareholder dilution Aug 09
FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia Jun 28
New major risk - Market cap size Jun 09
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication Jun 05
New major risk - Financial position May 16
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia May 08
New minor risk - Shareholder dilution Apr 10
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd Mar 12
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 Forum Mar 05 FSD Pharma Inc. has filed a Follow-on Equity Offering in the amount of $11.154232 million. Feb 19
FSD Pharma Inc. Announces Board Changes Jan 30
FSD Pharma Inc. Provides an Update Regarding Its Litigation with GBB Drink Lab, Inc Jan 18
GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case Jan 12 FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding Dec 07
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding Dec 05
FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding Nov 29
New major risk - Financial position Nov 29 FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding Nov 28
FSD Pharma Inc. Announces Change of CEO Nov 18
FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza Bokhari Oct 05
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis Sep 19
FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023 Aug 17
New minor risk - Shareholder dilution Aug 13
New minor risk - Shareholder dilution Aug 06
FSD Pharma Inc. Announces CEO Changes Jul 06
Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 Million Jun 22
FSD Pharma Inc. Announces Board Changes May 26
Founder recently bought CA$442k worth of stock Apr 13 FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
FSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Feb 08
FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic Pain Jan 31
FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS Jan 20
FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation Jan 18
FSD Pharma Inc. Announces Committee Appointments Jan 10
FSD Pharma Announces Changes to the Board of Directors Nov 29
Less than half of directors are independent Nov 16
FSD Pharma Inc. Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari Nov 12
FSD Pharma Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 30
FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201 Sep 07
FSD Pharma Inc. Elects Fernando Cugliari as Director Jun 28
FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate Updates Jun 01
FSD Pharma Inc. Announces Dismissal of Derivative Complaint May 08
FSD Pharma Inc., Annual General Meeting, Jun 23, 2022 May 07
Founder recently bought CA$63k worth of stock Apr 27
High number of new and inexperienced directors Apr 27
FSD Pharma Inc. Appoints David Allan and John Mcgraw to the Company's Advisory Board Apr 22
Founder recently bought CA$59k worth of stock Apr 14
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate Apr 13
FSD Pharma Inc. Announces Executive Appointments Apr 07
Founder recently bought CA$54k worth of stock Feb 28
An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million. Feb 26
Founder recently bought CA$51k worth of stock Feb 10
Founder recently bought CA$143k worth of stock Jan 03
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate Dec 17
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models) Dec 03
FSD Pharma Inc. (CNSX:HUGE) entered into a definitive agreement to acquire Lucid Psycheceuticals Inc. for CAD 9.7 million. Aug 26
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation Aug 25
Independent Director has left the company May 20
Independent Director has left the company May 20
Independent Director has left the company May 20
FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy May 11
Independent Director has left the company May 10
Chief Financial Officer has left the company May 10
Morganti & Co, P.C., Announces Settlement Approval for FSD Pharma Inc. Securities Class Action Feb 14
How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year? Feb 13
FSD Pharma Inc. Enters into an Equity Distribution Agreement with A.G.P./Alliance Global Partners Feb 12
New 90-day high: CA$2.95 Feb 09
Founder, President & Director Zeeshan Saeed has left the company Jan 30 FSD Pharma Inc. Continues to Pursue Its Strategy of Completing A Phase 2 Clinical
FSD Pharma Inc., Annual General Meeting, Jun 29, 2021 Jan 23
New 90-day high: CA$2.88 Jan 21
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of Fsd201 for the Treatment of Hospitalized Patients with Covid-19 Dec 17 Shareholder Returns QNTM CA Pharmaceuticals CA Market 7D -28.0% -0.5% -2.6% 1Y -94.8% -26.7% 15.2%
See full shareholder returns
Return vs Market: QNTM underperformed the Canadian Market which returned 15.2% over the past year.
Price Volatility Is QNTM's price volatile compared to industry and market? QNTM volatility QNTM Average Weekly Movement 17.4% Pharmaceuticals Industry Average Movement 12.0% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.4% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: QNTM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: QNTM's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Show more Quantum BioPharma Ltd. Fundamentals Summary How do Quantum BioPharma's earnings and revenue compare to its market cap? QNTM fundamental statistics Market cap CA$8.08m Earnings (TTM ) -CA$14.71m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) QNTM income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$10.24m Earnings -US$10.24m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 13:47 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Quantum BioPharma Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets
Show 0 more analysts 
